This Day On The Street
Continue to site right-arrow
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
TheStreet Open House

Health Stocks in Motion

Shares of Affymetrix (AFFX) were among the worst-performing health-related stocks Friday, falling 19% after the company posted second-quarter results that fell short of expectations and warned that third-quarter results would be below forecasts as well.

The biotech company reported earnings of $7.8 million, or 12 cents a share, on total sales of $84.1 million. Analysts polled by Thomson First Call were expecting earnings of 17 cents a share on sales of $88.1 million. A year ago the company earned $7 million, or 11 cents a share, on sales of $79.8 million.

Looking ahead, Affymetrix forecast a third-quarter loss of 6 cents a share on sales of $95 million. The earnings forecast includes charges of $17.5 million, or 27 cents a share, but excludes non-cash amortization of about $1 million, or 2 cents a share. Analysts had been expecting earnings of 29 cents a share on sales of $101.7 million. Shares were trading down $10.83 to $46.16.

Manor Care (HCR) rose modestly after the company reported second-quarter earnings that beat forecasts. The operator of nursing homes reported earnings of $37.9 million, or 43 cents a share, on sales of $833.8 million. Excluding items, the company would have earned 48 cents a share. Analysts were expecting earnings of 46 cents a share on sales of $828.8 million. A year ago the company earned $40.1 million, or 45 cents a share, on sales of $799.1 million. In addition to earnings, Manor Care said its board has authorized an additional $300 million for stock repurchases. At the end of the second quarter, the company about $44 million remaining under its previously approved buyback plan. Shares were trading up 5 cents to $36.55.

Shares of Beckman Coulter (BEC) fell 15% after the maker of testing instruments posted second-quarter earnings that fell well below expectations and slashed its 2005 guidance. The company reported earnings of $47.7 million, or 73 cents a share, on sales of $618.8 million. Excluding items, the company would have posted earnings of $51.9 million, or 80 cents a share. Analysts were expecting earnings of 92 cents a share on sales of $641.5 million. A year ago the company earned $58.3 million, or 88 cents a share, on sales of $597.3 million.

1 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Jim Cramer and Stephanie Link reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

Jim Cramer's protégé, David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
Try it NOW
Try it NOW
Try it NOW

Check Out Our Best Services for Investors

Dividend Stock Advisor

Jim Cramer's protégé, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
Try it NOW
Try it NOW
Try it NOW
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!

Markets

DOW 17,164.95 -251.90 -1.45%
S&P 500 1,994.99 -26.26 -1.30%
NASDAQ 4,635.24 -48.1670 -1.03%

Partners Compare Online Brokers

Free Reports

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs